Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sujith Samarasinghe
  • Katherine Clesham
  • Simona Iacobelli
  • Giulia Sbianchi
  • Cora Knol
  • Rose-Marie Hamladji
  • Gerard Socié
  • Mahmoud Aljurf
  • Mickey Koh
  • Henrik Sengeloev
  • Jean-Hugues Dalle
  • Stephen Robinson
  • Maria Teresa Van Lint
  • Constantijn J M Halkes
  • Dietrich Beelen
  • Ghulam J Mufti
  • John Snowden
  • Didier Blaise
  • Regis Peffault de Latour
  • Judith Marsh
  • Carlo Dufour
  • Antonio M Risitano
  • Severe Aplastic Anaemia Working Party of the EBMT
Vis graf over relationer

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti-thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14-0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35-0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Hematology
Vol/bind94
Udgave nummer1
Sider (fra-til)80-86
Antal sider7
ISSN0361-8609
DOI
StatusUdgivet - 1 jan. 2019

ID: 56566007